Aastrom Biosciences, Inc. - Product Pipeline Review - Q4 2010

Global Markets Direct, November 2010, Pages: 53

Aastrom Biosciences, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Aastrom Biosciences, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Aastrom Biosciences, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Aastrom Biosciences, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Aastrom Biosciences, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Aastrom Biosciences, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Aastrom Biosciences, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Aastrom Biosciences, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Aastrom Biosciences, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Aastrom Biosciences, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Aastrom Biosciences, Inc. and identify potential opportunities in those areas.

List of Tables
List of Figures
Aastrom Biosciences, Inc. Snapshot
Aastrom Biosciences, Inc. Overview
Key Information
Key Facts
Aastrom Biosciences, Inc. – Research and Development Overview
Key Therapeutic Areas
Aastrom Biosciences, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Aastrom Biosciences, Inc. – Pipeline Products Glance
Aastrom Biosciences, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Aastrom Biosciences, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Aastrom Biosciences, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Aastrom Biosciences, Inc. – Drug Profiles
Bone Repair Cells
Product Description
Mechanism of Action
R&D Progress
Autologous Bone Marrow Cells
Product Description
Mechanism of Action
R&D Progress
Cardiac Repair Cells
Product Description
Mechanism of Action
R&D Progress
Vascular Repair Cells
Product Description
Mechanism of Action
R&D Progress
Neural Repair Cells
Product Description
Mechanism of Action
R&D Progress
Aastrom Biosciences, Inc. – Pipeline Analysis
Aastrom Biosciences, Inc. – Pipeline Products by Therapeutic Class
Aastrom Biosciences, Inc. Pipeline Products By Target
Aastrom Biosciences, Inc. – Pipeline Products by Route of Administration
Aastrom Biosciences, Inc. – Pipeline Products by Molecule Type
Aastrom Biosciences, Inc. – Recent Pipeline Updates
Aastrom Biosciences, Inc. – Company Statement
Aastrom Biosciences, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Nov 18, 2010: Aastrom Reports Positive Second Interim Analysis Of Phase IIb RESTORE-CLI Clinical Trial
Oct 20, 2010: Aastrom Submits Special Protocol Assessment To FDA for Its Phase 3 CLI Program
Oct 20, 2010: Aastrom Submits Special Protocol Assessment To FDA For Phase III CLI Program
Oct 18, 2010: Aastrom Receives FDA Fast Track Designation For Phase III CLI Program
Oct 18, 2010: Aastrom Receives FDA Fast Track Designation for Phase 3 CLI Program
Jul 14, 2010: Aastrom Initiates IMPACT-DCM Extension Study For Control Patients
Jul 06, 2010: Aastrom To Pursue Phase III Clinical Program In Critical Limb Ischemia
Nov 16, 2009: Aastrom Presents Updates And Results From Vascular Program Presented At An American Heart Association Satellite Symposium
Nov 10, 2009: Aastrom To Initiate Second Phase II Clinical Trial For Treatment Of Severe Chronic Heart Failure
Oct 30, 2009: Aastrom Announces Achievement Of Milestone In U.S. Phase IIb Critical Limb Ischemia Clinical Trial
Financial Deals Landscape
Aastrom Biosciences, Inc., Deals Volume Summary, 2004 to YTD 2010
Aastrom Biosciences, Inc., Deals Summary By Region, 2004 to YTD 2010
Aastrom Biosciences, Inc., Deals Summary, 2004 to YTD 2010
Aastrom Biosciences, Inc. Detailed Deal Summary
Equity Offering
Aastrom Biosciences Completes Underwritten Public Offering Of $14 Million
Aastrom Biosciences Completes Private Placement Of Upto $15 Million
Aastrom Biosciences Completes Private Placement Of $13.5 Million
Aastrom Biosciences Completes Private Placement Of $25.5 Million
Aastrom Biosciences Completes Private Placement Of $12 Million
Aastrom Biosciences Completes Private Placement Of $10 Million
Aastrom Biosciences Completes Private Placement Of $9.12 Million
Aastrom Biosciences Signs Collaboration Agreement With Orthovita
Licensing Agreements
Aastrom Biosciences Enters Into Licensing Agreement With RealBio Technology
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• eLEARNING - Global Strategic Business Report
• Charter Schools - Global Outlook
• Aerospace and Defense Industry - Global Strategic Business Report
• Sports and Fitness Nutrition - Global Strategic Business Report
• Education Services - Global Strategic Business Report
• North America – Smart Weapons Markets and Technologies Outlook – 2013-2020
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Defense Robotics - Global Strategic Business Report
• Private Tutoring - Global Strategic Business Report
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans